  |
 |
D. Are There Contraindications to Opioid Therapy That
Cannot Be Resolved?
OBJECTIVE
Avoid inappropriate or harmful
therapy.
BACKGROUND
Although there are few absolute
contraindications to the use of opioids in chronic pain, many factors
must be considered prior to initiating therapy. The clinician must carefully
weigh risks and benefits of chronic opioid therapy, and should discuss
them with the patient and family/care giver where appropriate. Patients
with relative contraindications pose a higher risk of legal and clinical
problems.
RECOMMENDATIONS
- Opioid therapy should not be used in the following situations (absolute
contraindications):
- Allergy to opioid agents (may be resolved by switching agents)
- Co-administration of drug capable of inducing life-limiting drug-drug
interaction
- Active diversion of controlled substances (providing the medication
to someone for whom it was not intended)
- Opioid therapy should be used only after careful consideration of
the risks and benefits (relative contraindications):
- Acute psychiatric instability or high suicide risk
- History of intolerance, serious adverse effects, or lack of efficacy
of opioid therapy
- Meets DSM-IV criteria for current substance use disorder (DSM IV,
1994)
- Inability to manage opioid therapy responsibly (e.g., cognitively
impaired)
- Unwillingness or inability to comply with treatment plan
- Unwillingness to adjust at-risk activities resulting in serious
re-injury
- Social instability
- Patient with sleep apnea not on CPAP
- Elderly patients
- COPD patients
- Consider consultation with an appropriate specialist if legal or
clinical problems indicate that more intensive care related to opioid
management is indicated. A patient with substance use problem should
be referred to a substance use specialty for concurrent treatment
of substance
use.
DISCUSSION
Absolute contraindications
- Allergy to opioid agents
Morphine causes the release of histamine, frequently resulting in
itching, but this is not an allergic reaction. True allergy to opioid
agents (e.g. anaphylaxis) is not common but does occur. Generally,
allergy to one opioid agent does not mean the patient is allergic
to other opioids; also switching to an agent in another opioid drug
class may be effective. For example, if a patient has a hypersensitivity
to a phenanthrene, then a diphenylheptane drug may be tried. (See
table below.) When patients report an "allergy" to all but
one agent (such as meperidine), the presence of a substance use disorder
should be considered. Consultation with an allergist may be helpful
to resolve these issues.
Table 1.
Classes of Opioid Medications
Phenanthrenes
Codeine
Hydrocodone
Hydromorphone
Levorphanol
Morphine
Oxycodone
|
Diphenylheptanes
Methadone
Propoxyphene
|
Phenylpiperidine
Fentanyl
Meperidine a
Other
Tramadol
|
a Meperidine is not recommended
for chronic pain because of the potential for accumulation of the neurotoxic
metabolite, normeperidine, and a potentially fatal drug interaction with
monoamine oxidase inhibitors (MAOIs).
- Co-administration of a drug capable of inducing
life limiting drug-drug interaction
Providers should carefully evaluate potential drug interactions prior
to initiating opioid therapy, (such as MAOI with concurrent meperidine
use, or propoxyphene and alcohol and other CNS depressants). (Note:
meperidine is not recommended for chronic pain because of this potentially
fatal
drug interaction and the potential for accumulation of the neurotoxic
metabolite, normeperidine, with regular dosing.)
- Active diversion of controlled substances
Diversion should be suspected when there are frequent requests for
early refills, atypically large quantities are required, when purposeful
misrepresentation
of the pain disorder is suspected, or when a urine drug screen (UDS)
is negative for the substance being prescribed, in the absence of
withdrawal
symptoms. Routine UDS often does not detect synthetic and semi-synthetic
opioids (methadone, oxycodone, fentanyl, hydrocodone, meperidine or
hydromorphone). Verified diversion is a crime and constitutes a strong
contraindication to prescribing additional medications, and consultation
with a pain specialist, psychiatrist, or addiction specialist may be
warranted.
Relative contraindications
- Acute psychiatric instability
Current serious suicidality, severe depression, or unstable bipolar
disorder or psychotic disorder precludes safe use of opioids, unless
the patient is closely monitored and professional staff or family members
administer the medication (Harden, 2002).
- Intolerance, serious adverse effects or history
of inadequate clinical response to opioids (lack of efficacy)
Although generally well tolerated, opioids have potential adverse effects
that may cause significant morbidity.
- Meets DSM-IVR criteria for current substance
use disorder (SUD) other than nicotine dependence
Current substance abuse or dependence increases the risk of drug-drug
interactions, addiction to prescribed opioids, and diversion. However,
use of a substance, whether legal or illegal, does not in itself constitute
a substance use disorder. A medical diagnosis of a SUD should be made
according to the Diagnostic and Statistical Manual-Version IV, Revised
(DSM-IV). A diagnosis of SUD requires that substance use is maladaptive
and results in clinically significant impairment or distress. Chronic
and appropriate use of prescribed opioids will cause cause physiologic
dependence and may result in tolerance. However, appropriate use of
opioids for chronic pain that results in improved function and quality
of life does not constitute a SUD. The term "pseudoaddiction"
describes prescription of an inadequate dose of opioids, leading to
attempts by the patient to seek additional pain relief through additional
medication.
The proper response to pseudoaddiction is to adjust the dose of opioids
to provide effective pain relief.
It is not clear whether a history of a SUD in sustained remission (>
12 months) is predictive of increased risk for development of addiction
in the context of opioid therapy. However, prudence dictates that the
provider consider the stability of remission, including the patient's
insight, participation in recovery activities such as self-help groups,
and social support. Providers should consider consultation with an addiction
specialist when the patient has a more recent history of a SUD, when
remission is unstable, or for patients with a history of prior opioid
addiction, intravenous drug use, or prescription drug abuse or dependence
(Large & Schug, 1995; Becker et al., 2000).
Substance Dependence (or addiction)
refers to a condition characterized by a presentation of three or more
of seven specific symptoms, defined in DSM-IV. Psychological dependence
or drug addiction is different from physiologic dependence. Substance
dependence
requires a higher level of intervention and management than substance
abuse.
- Inability to manage opioid therapy responsibly
Patients may repeatedly "lose" medication, may be unable
or unwilling to store the medication in a safe place, or may repeatedly
run short and ask for early refills, or obtain medication from more
than one physician or pharmacy. The likelihood of these problems can
be minimized by clearly specifying expectations prior to initiating
therapy through the use of the written contract agreement (See Appendix
C). Many patients respond to reminders and clear limit setting at the
first instance, but repeated occurrence makes continuing therapy difficult.
If a patient is cognitively impaired, assistance of a responsible
caregiver may be required.
- Unwillingness or inability to comply with
reasonable treatment plan
Treatment of chronic pain often requires a multidisciplinary approach
(such as physical therapy, relaxation training, or psychiatric treatment),
which requires active participation of the patient. Similarly, patients
must make lifestyle changes to accommodate chronic pain. Repeated failure
of the patient to follow through raises questions about the motivation
of the patient and the appropriateness of continued opioid therapy.
Patients must be counseled about this, and barriers to participation
should be addressed. When this fails to result in improved participation,
consideration must be given to discontinuing opioid therapy.
- Social instability
Patients living in chaotic or unsafe environments (e.g. homeless
shelter, living with others who are using cocaine) should not receive
opioids
until social stability is achieved.
EVIDENCE
| |
Recommendations |
Sources of Evidence |
QE |
Overall Quality |
R |
| 1 |
Absolute contraindications to opioid
therapy:
- Active diversion of controlled substances
|
Legal |
- |
- |
- |
| 2 |
Relative contraindications to opioid therapy:
- Psychiatric instability
- Adverse effect or lack of efficacy
- Current SUD
- Inability to manage therapy
- Noncompliance with treatment
- Social instability
- Sleep apnea not on CPAP
|
Harden, 2002
Joranson et al., 1992
Becker et al., 2002
Large & Schug, 1995
Working Group Consensus
|
III
III
I
III
III |
Fair |
C |
| 3 |
Consultation with an addiction specialist if
legal or clinical problems indicate that more intensive management
of opioids is indicated |
Working Group Consensus |
III |
Poor |
I |
QE = Quality of Evidence; R = Recommendation (See
Appendix A)
|